Shandong Weigao Group Medical Polymer Company Limited (Weigao Group) disclosed that it bought back 66,000 H shares on 9 October 2026 on the Hong Kong Stock Exchange under its current share-repurchase mandate.

The shares were repurchased within a price range of HK$3.245 to HK$3.31, representing a volume-weighted average cost of HK$3.29 per share. Total consideration amounted to HK$0.22 million.

Following the transaction, Weigao Group’s outstanding issued share capital (excluding treasury shares) decreased marginally by 0.0015 % to 4.46 billion shares. Treasury share holdings rose to 67.14 million, leaving the company’s total issued share count unchanged at 4.52 billion.

The buy-back forms part of the mandate approved on 29 May 2026, which authorises repurchases of up to 446.46 million shares. Aggregate repurchases executed under this mandate now stand at 9.81 million shares, equivalent to 2.20 % of the company’s issued share base at the time of authorisation.

Under Hong Kong listing rules, Weigao Group is subject to a 30-day moratorium on new share issues or sales of treasury shares, extending to 9 November 2026.